CA3179694A1 - Fusion proteins of ctl antigens for treating melanoma - Google Patents

Fusion proteins of ctl antigens for treating melanoma

Info

Publication number
CA3179694A1
CA3179694A1 CA3179694A CA3179694A CA3179694A1 CA 3179694 A1 CA3179694 A1 CA 3179694A1 CA 3179694 A CA3179694 A CA 3179694A CA 3179694 A CA3179694 A CA 3179694A CA 3179694 A1 CA3179694 A1 CA 3179694A1
Authority
CA
Canada
Prior art keywords
seq
clt
fusion protein
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3179694A
Other languages
English (en)
French (fr)
Inventor
George KASSIOTIS
George Young
Jan ATTIG
Ambrosius SNIJDERS
David Perkins
Fabio MARINO
Ray Jupp
Magdalena VON ESSEN
Peter Mason
Nicola TERNETTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Francis Crick Institute Ltd
Enara Bio Ltd
Original Assignee
The Francis Crick Institute Ltd
Enara Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Francis Crick Institute Ltd, Enara Bio Ltd filed Critical The Francis Crick Institute Ltd
Publication of CA3179694A1 publication Critical patent/CA3179694A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3179694A 2020-04-17 2021-04-19 Fusion proteins of ctl antigens for treating melanoma Pending CA3179694A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170174 2020-04-17
EP20170174.5 2020-04-17
PCT/US2021/028029 WO2021212123A1 (en) 2020-04-17 2021-04-19 Fusion proteins of ctl antigens for treating melanoma

Publications (1)

Publication Number Publication Date
CA3179694A1 true CA3179694A1 (en) 2021-10-21

Family

ID=70295067

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3179694A Pending CA3179694A1 (en) 2020-04-17 2021-04-19 Fusion proteins of ctl antigens for treating melanoma

Country Status (6)

Country Link
US (1) US20230167163A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136097A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522198A (cg-RX-API-DMAC7.html)
CN (1) CN116057067A (cg-RX-API-DMAC7.html)
CA (1) CA3179694A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021212123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3994156A1 (en) 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
MX2022000263A (es) * 2019-07-05 2022-02-03 The Francis Crick Institute Ltd Nuevos antigenos y metodos contra el cancer.
EP4136096A1 (en) * 2020-04-17 2023-02-22 The Francis Crick Institute Limited Antigen pool
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
TR200100916T2 (cg-RX-API-DMAC7.html) * 1998-07-14 2002-06-21 Corixa@@Corporation
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1586330A1 (en) * 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
CN101638440B (zh) * 2008-07-29 2011-10-26 中国人民解放军军事医学科学院基础医学研究所 一种可诱发机体抗肿瘤免疫的异种抗原-Fc融合蛋白及其应用
CN119978090A (zh) * 2018-10-19 2025-05-13 弗朗西斯·克里克研究所有限公司 新的癌抗原和方法
WO2020260897A1 (en) * 2019-06-28 2020-12-30 The Francis Crick Institute Limited Novel cancer antigens and methods
MX2022000263A (es) * 2019-07-05 2022-02-03 The Francis Crick Institute Ltd Nuevos antigenos y metodos contra el cancer.

Also Published As

Publication number Publication date
EP4136097A1 (en) 2023-02-22
JP2026086469A (ja) 2026-05-26
US20230167163A1 (en) 2023-06-01
JP2023522198A (ja) 2023-05-29
WO2021212123A1 (en) 2021-10-21
CN116057067A (zh) 2023-05-02

Similar Documents

Publication Publication Date Title
US20230167163A1 (en) Fusion proteins of ctl antigens for treating melanoma
US20250360206A1 (en) Cancer antigens and methods
EP3993826B1 (en) Novel cancer antigens and methods
JP2025032114A (ja) 新規な癌抗原及び方法
US20220211760A1 (en) Novel cancer antigens and methods
US20220220175A1 (en) Novel cancer antigens and methods
US20230302109A1 (en) Antigen pool
EA052615B1 (ru) Новые раковые антигены и сопутствующие способы
EA052067B1 (ru) Новые раковые антигены и сопутствующие способы
EA053293B1 (ru) Новые раковые антигены и сопутствующие способы

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250421

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250422

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250618

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250618

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250618

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250618

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250618

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601